patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_746540 | REC_0008301 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 23 | 13.4 | 65 | male | 0 | 14 | 5.9 | 0 | entrectinib 600 mg daily | 83 | true | MSI-H | 2026-03-15T05:35:58.898416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333759 | REC_0008302 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 10.4 | 69 | female | 0 | 18 | 4.8 | 2 | osimertinib 80 mg daily | 9.6 | true | MSS | 2026-03-15T05:35:58.898646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831974 | REC_0008303 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 9.1 | 79 | female | 2 | 9 | 6.2 | 3 | sotorasib 960 mg daily | 5.8 | true | MSS | 2026-03-15T05:35:58.898876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747244 | REC_0008304 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 9.7 | 64 | male | 1 | 4 | 6 | 5 | sotorasib 960 mg daily | 10.1 | false | MSS | 2026-03-15T05:35:58.899106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_582848 | REC_0008305 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 16.5 | 77 | female | 2 | 10 | 5.6 | 4 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:58.899341+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685055 | REC_0008306 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 17.7 | 65 | female | 0 | 9 | 5.7 | 7 | alectinib 600 mg BID | 9.6 | false | MSS | 2026-03-15T05:35:58.899577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271272 | REC_0008307 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 15.7 | 74 | female | 1 | 28 | 5.2 | 7 | osimertinib 80 mg daily | 9.4 | false | MSI-H | 2026-03-15T05:35:58.899811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346880 | REC_0008308 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 10.8 | 77 | female | 1 | 11 | 6.5 | 6 | osimertinib 80 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:58.900162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500950 | REC_0008309 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 4.2 | 78 | female | 2 | 22 | 5.2 | 9 | pembrolizumab 200 mg q3w | 10.6 | false | MSS | 2026-03-15T05:35:58.900414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356295 | REC_0008310 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 8.8 | 56 | male | 1 | 48 | 4.9 | 2 | pembrolizumab 200 mg q3w | 23.9 | true | MSS | 2026-03-15T05:35:58.900649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304182 | REC_0008311 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 5.3 | 72 | female | 1 | 15 | 5.5 | 3 | alectinib 600 mg BID | 9.6 | true | MSS | 2026-03-15T05:35:58.900893+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554020 | REC_0008312 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 23 | 60 | male | 0 | 14 | 4.3 | 7 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:58.901132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250107 | REC_0008313 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 13.4 | 51 | female | 0 | 9 | 6.8 | 8 | osimertinib 80 mg daily | 16.9 | true | MSI-H | 2026-03-15T05:35:58.901372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360741 | REC_0008314 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 31 | 6.2 | 67 | female | 1 | 17 | 5.3 | 0 | carboplatin + paclitaxel + pembrolizumab | 44.6 | true | MSS | 2026-03-15T05:35:58.901605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545918 | REC_0008315 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.9 | 73 | female | 2 | 8 | 6.7 | 3 | carboplatin + paclitaxel + pembrolizumab | 16.1 | false | MSS | 2026-03-15T05:35:58.901847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813935 | REC_0008316 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.9 | 60 | female | 0 | 54 | 4.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 6 | true | MSS | 2026-03-15T05:35:58.902084+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437565 | REC_0008317 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 13.2 | 71 | female | 2 | 14 | 3.6 | 7 | sotorasib 960 mg daily | 14.4 | true | MSS | 2026-03-15T05:35:58.902323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397439 | REC_0008318 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 16.1 | 57 | female | 0 | 25 | 5.4 | 6 | alectinib 600 mg BID | 10.6 | true | MSI-H | 2026-03-15T05:35:58.902559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150304 | REC_0008319 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 14.2 | 62 | male | 1 | 22 | 4.4 | 6 | sotorasib 960 mg daily | 14.8 | false | MSS | 2026-03-15T05:35:58.902802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750222 | REC_0008320 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 10.7 | 67 | female | 1 | 14 | 8.2 | 6 | entrectinib 600 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:58.903037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_374084 | REC_0008321 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 9.3 | 70 | female | 1 | 18 | 5.7 | 5 | entrectinib 600 mg daily | 8.5 | false | MSS | 2026-03-15T05:35:58.903373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457582 | REC_0008322 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 7.7 | 67 | female | 1 | 25 | 5.1 | 0 | sotorasib 960 mg daily | 19.4 | false | MSS | 2026-03-15T05:35:58.903610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403094 | REC_0008323 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 9.9 | 62 | male | 1 | 21 | 6.4 | 6 | entrectinib 600 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:58.903847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579384 | REC_0008324 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 13.8 | 83 | female | 1 | 12 | 8.4 | 6 | sotorasib 960 mg daily | 9.2 | false | MSI-H | 2026-03-15T05:35:58.904207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692579 | REC_0008325 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 26 | 11.9 | 67 | female | 0 | 15 | 6.5 | 0 | osimertinib 80 mg daily | 28.4 | true | MSS | 2026-03-15T05:35:58.904468+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788315 | REC_0008326 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 3.5 | 80 | male | 0 | 64 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.6 | true | MSS | 2026-03-15T05:35:58.904708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_682119 | REC_0008327 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 7.3 | 68 | female | 1 | 18 | 8.3 | 4 | entrectinib 600 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:58.904942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764535 | REC_0008328 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 13.9 | 78 | female | 2 | 12 | 5 | 8 | sotorasib 960 mg daily | 13.9 | false | MSS | 2026-03-15T05:35:58.905180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722936 | REC_0008329 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 4.6 | 63 | male | 1 | 53 | 5.2 | 8 | carboplatin + paclitaxel + pembrolizumab | 17.5 | false | MSS | 2026-03-15T05:35:58.905422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208726 | REC_0008330 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 12.7 | 65 | female | 1 | 12 | 6 | 5 | sotorasib 960 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:58.905663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318381 | REC_0008331 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.6 | 65 | female | 0 | 44 | 6.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 14 | false | MSS | 2026-03-15T05:35:58.905895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_299130 | REC_0008332 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 15.2 | 64 | female | 1 | 14 | 5 | 6 | osimertinib 80 mg daily | 7.4 | true | MSS | 2026-03-15T05:35:58.906147+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188853 | REC_0008333 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.7 | 73 | female | 1 | 58 | 5.4 | 3 | pembrolizumab 200 mg q3w | 16.1 | false | MSS | 2026-03-15T05:35:58.906380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106253 | REC_0008334 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 16.6 | 64 | female | 0 | 11 | 7.2 | 5 | sotorasib 960 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:58.906711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712012 | REC_0008335 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 6.9 | 67 | female | 0 | 25 | 4.7 | 2 | alectinib 600 mg BID | 21 | false | MSS | 2026-03-15T05:35:58.906959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456450 | REC_0008336 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 13.2 | 79 | female | 2 | 4 | 3.5 | 1 | sotorasib 960 mg daily | 17.4 | false | MSI-H | 2026-03-15T05:35:58.907205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919046 | REC_0008337 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 8.9 | 68 | male | 0 | 14 | 4.5 | 2 | sotorasib 960 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:58.907455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233472 | REC_0008338 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 12.7 | 67 | female | 0 | 24 | 3.3 | 2 | osimertinib 80 mg daily | 22.3 | true | MSI-H | 2026-03-15T05:35:58.907703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395907 | REC_0008339 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 1.5 | 69 | male | 1 | 85 | 5.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.7 | true | MSS | 2026-03-15T05:35:58.907956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_266797 | REC_0008340 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 12 | 57 | male | 0 | 9 | 6 | 1 | entrectinib 600 mg daily | 9.4 | false | MSS | 2026-03-15T05:35:58.908268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228093 | REC_0008341 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 35 | 12.3 | 78 | female | 1 | 13 | 7.1 | 4 | osimertinib 80 mg daily | 5.4 | true | MSS | 2026-03-15T05:35:58.908533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281682 | REC_0008342 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 12.7 | 70 | female | 1 | 20 | 4.6 | 6 | pembrolizumab 200 mg q3w | 9.1 | false | MSS | 2026-03-15T05:35:58.908784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943076 | REC_0008343 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 13 | 69 | female | 1 | 23 | 4.1 | 2 | osimertinib 80 mg daily | 28.6 | false | MSS | 2026-03-15T05:35:58.909032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629200 | REC_0008344 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 9.6 | 69 | female | 0 | 9 | 5.2 | 7 | osimertinib 80 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:58.909268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328824 | REC_0008345 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 8.2 | 67 | female | 0 | 32 | 7.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 7.9 | true | MSS | 2026-03-15T05:35:58.909501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581234 | REC_0008346 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.3 | 80 | female | 2 | 63 | 5.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.5 | true | MSS | 2026-03-15T05:35:58.909738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_348578 | REC_0008347 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 15 | 5.3 | 67 | male | 0 | 16 | 4.5 | 6 | alectinib 600 mg BID | 9.1 | false | MSS | 2026-03-15T05:35:58.910103+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824750 | REC_0008348 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 7.6 | 63 | male | 0 | 33 | 3.9 | 6 | pembrolizumab 200 mg q3w | 8.4 | false | MSS | 2026-03-15T05:35:58.910362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590329 | REC_0008349 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 32 | 5.9 | 75 | female | 2 | 9 | 7.7 | 8 | pembrolizumab 200 mg q3w | 6.5 | false | MSS | 2026-03-15T05:35:58.910598+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173134 | REC_0008350 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 12.2 | 58 | female | 0 | 9 | 3.9 | 4 | alectinib 600 mg BID | 10 | true | MSS | 2026-03-15T05:35:58.910839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389585 | REC_0008351 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13 | 56 | female | 1 | 11 | 5.4 | 4 | entrectinib 600 mg daily | 6.5 | true | MSS | 2026-03-15T05:35:58.911079+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427695 | REC_0008352 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 5.6 | 60 | female | 0 | 57 | 4 | 6 | pembrolizumab 200 mg q3w | 5.6 | false | MSS | 2026-03-15T05:35:58.911315+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386257 | REC_0008353 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11.3 | 76 | female | 1 | 23 | 4.8 | 6 | osimertinib 80 mg daily | 14.6 | true | MSI-H | 2026-03-15T05:35:58.911560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753006 | REC_0008354 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 10.5 | 69 | female | 1 | 23 | 6.1 | 1 | osimertinib 80 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:58.911806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_921146 | REC_0008355 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.2 | 68 | female | 1 | 16 | 6.5 | 7 | alectinib 600 mg BID | 8.1 | true | MSI-H | 2026-03-15T05:35:58.912057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634815 | REC_0008356 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 23 | 7.6 | 77 | female | 3 | 14 | 4.2 | 0 | sotorasib 960 mg daily | 22.1 | true | MSS | 2026-03-15T05:35:58.912433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566232 | REC_0008357 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 15.3 | 77 | female | 1 | 26 | 4 | 2 | entrectinib 600 mg daily | 22.5 | false | MSI-H | 2026-03-15T05:35:58.912700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522669 | REC_0008358 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 8.9 | 70 | female | 1 | 49 | 5.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 17.1 | true | MSS | 2026-03-15T05:35:58.912964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423990 | REC_0008359 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 11.4 | 80 | female | 2 | 18 | 5.2 | 10 | osimertinib 80 mg daily | 7.3 | false | MSI-H | 2026-03-15T05:35:58.913223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558124 | REC_0008360 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 15.3 | 68 | female | 0 | 20 | 4.8 | 1 | alectinib 600 mg BID | 15.1 | false | MSI-H | 2026-03-15T05:35:58.913630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590430 | REC_0008361 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 2.7 | 54 | male | 0 | 10 | 5.2 | 1 | alectinib 600 mg BID | 20.5 | true | MSS | 2026-03-15T05:35:58.913914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342223 | REC_0008362 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 8.9 | 67 | female | 0 | 25 | 4.1 | 1 | osimertinib 80 mg daily | 16.7 | false | MSS | 2026-03-15T05:35:58.914167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_100843 | REC_0008363 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 7.1 | 89 | female | 2 | 15 | 4.6 | 7 | pembrolizumab 200 mg q3w | 6.2 | true | MSS | 2026-03-15T05:35:58.914428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758727 | REC_0008364 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 7.2 | 57 | male | 0 | 9 | 5.1 | 7 | osimertinib 80 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:58.914697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381536 | REC_0008365 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 10.7 | 63 | female | 1 | 15 | 5.2 | 5 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:58.914985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522817 | REC_0008366 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 15.9 | 65 | female | 1 | 11 | 6.8 | 1 | osimertinib 80 mg daily | 18.7 | false | MSS | 2026-03-15T05:35:58.915251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643176 | REC_0008367 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 15 | 10.3 | 68 | female | 0 | 26 | 5.6 | 4 | osimertinib 80 mg daily | 7.1 | false | MSS | 2026-03-15T05:35:58.915532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808687 | REC_0008368 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 12.6 | 49 | female | 0 | 19 | 7.7 | 6 | entrectinib 600 mg daily | 9.1 | true | MSI-H | 2026-03-15T05:35:58.915790+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378192 | REC_0008369 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 12.3 | 75 | female | 2 | 16 | 5.3 | 7 | sotorasib 960 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:58.916043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242036 | REC_0008370 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.2 | 66 | male | 0 | 10 | 5.6 | 3 | osimertinib 80 mg daily | 7.8 | false | MSI-H | 2026-03-15T05:35:58.916426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108418 | REC_0008371 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 17.9 | 54 | male | 0 | 18 | 5.7 | 2 | entrectinib 600 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:58.916700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516585 | REC_0008372 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 13 | 14 | 65 | female | 0 | 22 | 5.4 | 2 | alectinib 600 mg BID | 11.8 | true | MSI-H | 2026-03-15T05:35:58.916986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854987 | REC_0008373 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 10.5 | 74 | female | 2 | 15 | 5.3 | 5 | sotorasib 960 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:58.917327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358474 | REC_0008374 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 7.5 | 66 | female | 1 | 11 | 6.1 | 6 | alectinib 600 mg BID | 14.7 | false | MSS | 2026-03-15T05:35:58.917573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893608 | REC_0008375 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 7.1 | 66 | female | 1 | 13 | 5.5 | 2 | pembrolizumab 200 mg q3w | 14.9 | false | MSS | 2026-03-15T05:35:58.917827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_206544 | REC_0008376 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 8.7 | 73 | male | 1 | 9 | 4.5 | 1 | osimertinib 80 mg daily | 20 | true | MSS | 2026-03-15T05:35:58.918073+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305554 | REC_0008377 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.2 | 75 | female | 0 | 28 | 6.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:58.918304+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933311 | REC_0008378 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 11.4 | 69 | female | 1 | 13 | 5.9 | 1 | alectinib 600 mg BID | 17.9 | false | MSS | 2026-03-15T05:35:58.918537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782383 | REC_0008379 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 9.2 | 68 | female | 1 | 20 | 2.2 | 1 | alectinib 600 mg BID | 22.1 | false | MSS | 2026-03-15T05:35:58.918805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679736 | REC_0008380 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 12.8 | 70 | male | 2 | 10 | 6.2 | 4 | entrectinib 600 mg daily | 20.4 | false | MSS | 2026-03-15T05:35:58.919057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108928 | REC_0008381 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 11.9 | 71 | female | 1 | 17 | 5.7 | 6 | osimertinib 80 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:58.919295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_484635 | REC_0008382 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 13.6 | 67 | female | 1 | 8 | 6.3 | 8 | osimertinib 80 mg daily | 7.4 | false | MSI-H | 2026-03-15T05:35:58.919529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_851727 | REC_0008383 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 15 | 72 | male | 2 | 21 | 6.5 | 3 | sotorasib 960 mg daily | 15.6 | true | MSS | 2026-03-15T05:35:58.919828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390469 | REC_0008384 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 10.4 | 75 | female | 2 | 12 | 5 | 5 | osimertinib 80 mg daily | 13.5 | true | MSI-H | 2026-03-15T05:35:58.920116+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835615 | REC_0008385 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 14.7 | 74 | female | 2 | 16 | 4.1 | 5 | alectinib 600 mg BID | 8.2 | true | MSS | 2026-03-15T05:35:58.920365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744405 | REC_0008386 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 14.4 | 66 | female | 1 | 18 | 6 | 5 | entrectinib 600 mg daily | 14.6 | true | MSS | 2026-03-15T05:35:58.920713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592638 | REC_0008387 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 8.9 | 63 | female | 1 | 9 | 5.4 | 1 | alectinib 600 mg BID | 14.2 | true | MSS | 2026-03-15T05:35:58.920955+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760286 | REC_0008388 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 15.1 | 63 | male | 1 | 15 | 3.9 | 6 | sotorasib 960 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:35:58.921191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468728 | REC_0008389 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 7.4 | 56 | male | 0 | 12 | 5.3 | 1 | pembrolizumab 200 mg q3w | 12.7 | false | MSS | 2026-03-15T05:35:58.921434+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824764 | REC_0008390 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 16.6 | 69 | female | 0 | 12 | 4.6 | 5 | osimertinib 80 mg daily | 9.9 | true | MSI-H | 2026-03-15T05:35:58.921699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859556 | REC_0008391 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 5 | 65 | male | 0 | 53 | 4 | 4 | pembrolizumab 200 mg q3w | 9.9 | true | MSS | 2026-03-15T05:35:58.921938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_746307 | REC_0008392 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 11.1 | 59 | female | 1 | 18 | 5.6 | 5 | alectinib 600 mg BID | 9.8 | true | MSI-H | 2026-03-15T05:35:58.922171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355326 | REC_0008393 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.5 | 68 | female | 0 | 28 | 3.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.8 | true | MSS | 2026-03-15T05:35:58.922404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976141 | REC_0008394 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 4.3 | 69 | male | 0 | 25 | 4.9 | 3 | pembrolizumab 200 mg q3w | 10.4 | false | MSS | 2026-03-15T05:35:58.922637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136499 | REC_0008395 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.5 | 77 | female | 2 | 25 | 4.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.6 | false | MSS | 2026-03-15T05:35:58.922867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466114 | REC_0008396 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 22 | 12.4 | 71 | female | 1 | 5 | 4.2 | 0 | osimertinib 80 mg daily | 25.7 | false | MSI-H | 2026-03-15T05:35:58.923097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597514 | REC_0008397 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 11 | 19 | 77 | female | 2 | 11 | 3.8 | 1 | osimertinib 80 mg daily | 30 | true | MSS | 2026-03-15T05:35:58.923330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159043 | REC_0008398 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 9.9 | 73 | female | 1 | 21 | 4.8 | 2 | osimertinib 80 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:58.923554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222556 | REC_0008399 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 5.5 | 62 | female | 1 | 22 | 5.5 | 7 | osimertinib 80 mg daily | 8.3 | true | MSS | 2026-03-15T05:35:58.923847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473844 | REC_0008400 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 6.5 | 64 | male | 1 | 51 | 6.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.7 | false | MSS | 2026-03-15T05:35:58.924144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.